Literature DB >> 16595594

Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: a preliminary study.

Naga Chalasani1, Raj Vuppalanchi, Nandita S Raikwar, Mark A Deeg.   

Abstract

CONTEXT: Recent studies demonstrated that de novo lipogenesis is increased in patients with nonalcoholic fatty liver disease (NAFLD). Patients with NAFLD also have plasma lipid abnormalities. These lipid abnormalities may in part be related to insulin resistance, which is common in patients with NAFLD. Insulin resistance is associated with alterations in proteins involved in lipid metabolism including glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD), which is involved in triglyceride metabolism.
OBJECTIVE: The objective of the study was to determine whether alterations in serum and hepatic levels of GPI-PLD occur in patients with NAFLD. DESIGN AND PATIENTS: We examined the following: 1) levels of serum GPI-PLD in nondiabetics with nonalcoholic steatohepatitis, compared with matched controls; 2) hepatic expression of GPI-PLD mRNA in patients with normal liver or NAFLD; and 3) effect of overexpressing GPI-PLD vs. beta-galactosidase (control) on global gene expression in a human hepatoma cell line.
RESULTS: The serum levels of GPI-PLD were significantly higher in patients with nonalcoholic steatohepatitis than in matched controls (119 +/- 24 vs.105 +/- 15 microg/ml, P = 0.047). The hepatic expression of GPI-PLD mRNA was increased nearly 3-fold in NAFLD patients, compared with patients with normal liver (3.1 +/- 2.6 vs. 1.1 +/- 1.0 arbitrary units per microgram total RNA, P = 0.026). Finally, overexpressing GPI-PLD was associated with an increase in de novo lipogenesis genes.
CONCLUSIONS: Patients with NAFLD have elevated serum levels and hepatic expression of GPI-PLD, and its overexpression in vitro is associated with increased expression of de novo lipogenesis genes. These results suggest that GPI-PLD may play a role in the pathogenesis of NAFLD and/or its metabolic features and warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16595594     DOI: 10.1210/jc.2006-0075

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 2.  What should we recommend to our patients with NAFLD regarding alcohol use?

Authors:  Suthat Liangpunsakul; Naga Chalasani
Journal:  Am J Gastroenterol       Date:  2012-07       Impact factor: 10.864

3.  Positive feedback regulation between adiponectin and T-cadherin impacts adiponectin levels in tissue and plasma of male mice.

Authors:  Keisuke Matsuda; Yuya Fujishima; Norikazu Maeda; Takuya Mori; Ayumu Hirata; Ryohei Sekimoto; Yu Tsushima; Shigeki Masuda; Masaya Yamaoka; Kana Inoue; Hitoshi Nishizawa; Shunbun Kita; Barbara Ranscht; Tohru Funahashi; Iichiro Shimomura
Journal:  Endocrinology       Date:  2014-12-16       Impact factor: 4.736

Review 4.  Molecular mechanisms involved in NAFLD progression.

Authors:  Mariano Malaguarnera; Michelino Di Rosa; Ferdinando Nicoletti; Lucia Malaguarnera
Journal:  J Mol Med (Berl)       Date:  2009-04-08       Impact factor: 4.599

5.  Serum glypican4 and glycosylphosphatidylinositol-specific phospholipase D levels are associated with adipose tissue insulin resistance in obese subjects with different glucose metabolism status.

Authors:  K Zhang; H Zhu; L Wang; H Yang; H Pan; F Gong
Journal:  J Endocrinol Invest       Date:  2020-08-20       Impact factor: 4.256

6.  Plasma glycosylphosphatidylinositol-specific phospholipase D predicts the change in insulin sensitivity in response to a low-fat but not a low-carbohydrate diet in obese women.

Authors:  Dona L Gray; Kevin D O'Brien; David A D'Alessio; Bonnie J Brehm; Mark A Deeg
Journal:  Metabolism       Date:  2008-04       Impact factor: 8.694

7.  Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease.

Authors:  Jonas B Nielsen; Oren Rom; Ida Surakka; Sarah E Graham; Wei Zhou; Tanmoy Roychowdhury; Lars G Fritsche; Sarah A Gagliano Taliun; Carlo Sidore; Yuhao Liu; Maiken E Gabrielsen; Anne Heidi Skogholt; Brooke Wolford; William Overton; Ying Zhao; Jin Chen; He Zhang; Whitney E Hornsby; Akua Acheampong; Austen Grooms; Amanda Schaefer; Gregory J M Zajac; Luis Villacorta; Jifeng Zhang; Ben Brumpton; Mari Løset; Vivek Rai; Pia R Lundegaard; Morten S Olesen; Kent D Taylor; Nicholette D Palmer; Yii-Der Chen; Seung H Choi; Steven A Lubitz; Patrick T Ellinor; Kathleen C Barnes; Michelle Daya; Nicholas Rafaels; Scott T Weiss; Jessica Lasky-Su; Russell P Tracy; Ramachandran S Vasan; L Adrienne Cupples; Rasika A Mathias; Lisa R Yanek; Lewis C Becker; Patricia A Peyser; Lawrence F Bielak; Jennifer A Smith; Stella Aslibekyan; Bertha A Hidalgo; Donna K Arnett; Marguerite R Irvin; James G Wilson; Solomon K Musani; Adolfo Correa; Stephen S Rich; Xiuqing Guo; Jerome I Rotter; Barbara A Konkle; Jill M Johnsen; Allison E Ashley-Koch; Marilyn J Telen; Vivien A Sheehan; John Blangero; Joanne E Curran; Juan M Peralta; Courtney Montgomery; Wayne H-H Sheu; Ren-Hua Chung; Karen Schwander; Seyed M Nouraie; Victor R Gordeuk; Yingze Zhang; Charles Kooperberg; Alexander P Reiner; Rebecca D Jackson; Eugene R Bleecker; Deborah A Meyers; Xingnan Li; Sayantan Das; Ketian Yu; Jonathon LeFaive; Albert Smith; Tom Blackwell; Daniel Taliun; Sebastian Zollner; Lukas Forer; Sebastian Schoenherr; Christian Fuchsberger; Anita Pandit; Matthew Zawistowski; Sachin Kheterpal; Chad M Brummett; Pradeep Natarajan; David Schlessinger; Seunggeun Lee; Hyun Min Kang; Francesco Cucca; Oddgeir L Holmen; Bjørn O Åsvold; Michael Boehnke; Sekar Kathiresan; Goncalo R Abecasis; Y Eugene Chen; Cristen J Willer; Kristian Hveem
Journal:  Nat Commun       Date:  2020-12-18       Impact factor: 14.919

8.  Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.

Authors:  Xin Yuan; Dawn Waterworth; John R B Perry; Noha Lim; Kijoung Song; John C Chambers; Weihua Zhang; Peter Vollenweider; Heide Stirnadel; Toby Johnson; Sven Bergmann; Noam D Beckmann; Yun Li; Luigi Ferrucci; David Melzer; Dena Hernandez; Andrew Singleton; James Scott; Paul Elliott; Gerard Waeber; Lon Cardon; Timothy M Frayling; Jaspal S Kooner; Vincent Mooser
Journal:  Am J Hum Genet       Date:  2008-10       Impact factor: 11.025

9.  Insulin-mimicking bioactivities of acylated inositol glycans in several mouse models of diabetes with or without obesity.

Authors:  Susumu Suzuki; Chitose Suzuki; Yoshinori Hinokio; Yasushi Ishigaki; Hideki Katagiri; Makoto Kanzaki; Viatcheslav N Azev; Nilanjana Chakraborty; Marc d'Alarcao
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

10.  Endurance exercise training restores diabetes-induced alteration in circulating Glycosylphosphatidylinositol-specific phospholipase D levels in rats.

Authors:  Farzad Abdolmaleki; Ali Heidarianpour
Journal:  Diabetol Metab Syndr       Date:  2020-05-19       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.